Specifically, there is a compelling mechanistic rationale to extend this PAR-2 modulatory effect to chondrosarcoma (CHS), a malignant cartilage tumor characterized by profound ECM remodeling, immune evasion, and stemness-associated dedifferentiation. This evidence concerns the gene F2RL1 and chondrogenic neoplasm.